Intensity Therapeutics, Inc. (INTS) — Financial statements
Income statement, balance sheet, and cash flow for Intensity Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.03 | 0.00↓100.0% | 0.15 | 0.00 | 0.00 | |
| Gross Profit | -0.03 | 0.00↑100.0% | -0.15 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 7↓35.4% | 10↑119.3% | 5↓6.7% | 5↓12.4% | 6 | |
| General & Administrative Expenses | 5↓14.8% | 6↑72.3% | 4↑46.1% | 2↑13.0% | 2 | |
| Selling & Marketing Expenses | 0.00 | 0.00↑100.0% | -0.15 | 0.00 | 0.00 | |
| SG&A Expenses | 5↓14.8% | 6↑79.8% | 3↑40.0% | 2↑13.0% | 2 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.02 | |
| Operating Expenses | 12↓27.8% | 17↑102.9% | 8↑8.2% | 8↓5.8% | 8 | |
| Total Costs & Expenses | 12↓27.8% | 17↑99.4% | 8↑10.2% | 8↓5.8% | 8 | |
| Operating Results | ||||||
| Operating Income | -12↑27.8% | -17↓99.4% | -8↓10.2% | -8↑5.8% | -8 | |
| Depreciation & Amortization | 0.00 | 0.00↓100.0% | 0.15 | 0.00 | 0.00 | |
| EBITDA | -12↑26.4% | -16↓61.3% | -10↓34.5% | -8↑4.8% | -8 | |
| EBIT | -12↑26.4% | -16↓59.0% | -10↓36.4% | -8↑4.8% | -8 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.18↓42.7% | 0.31↑1552.6% | 0.02↑124.0% | -0.08↓460.1% | -0.01 | |
| Interest Income | 0.18↓42.7% | 0.31↓3.1% | 0.32↑12959.3% | 0.00↓4.9% | 0.00 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 0.31↑272.9% | 0.08↑387.7% | 0.02 | |
| Non-Operating Income | 0.00↑100.0% | -0.32↓116.6% | 2↑3928.0% | -0.05↑63.1% | -0.14 | |
| Other Income / Expenses | 0.37↑15.5% | 0.32↑114.3% | -2↓6834.4% | -0.03↓127.0% | 0.12 | |
| Income Before Tax | -12↑28.7% | -16↓54.4% | -11↓39.0% | -8↑4.0% | -8 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -12↑28.7% | -16↓54.4% | -11↓39.0% | -8↑4.0% | -8 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -12↑28.7% | -16↓54.4% | -11↓39.0% | -8↑4.0% | -8 | |
| Bottom-Line Net Income | -12↑28.7% | -16↓37.1% | -12↓56.4% | -8↑4.0% | -8 | |
| EPS (Basic) | -8.56↑70.7% | -29.25↑15.2% | -34.50↑37.8% | -55.50↑4.3% | -58.00 | |
| EPS (Diluted) | -8.56↑70.7% | -29.25↑15.2% | -34.50↑37.8% | -55.50↑4.3% | -58.00 | |
| Weighted Average Shares | 14↑2338.4% | 0.56↑81.7% | 0.31↑124.5% | 0.14↑0.0% | 0.14 | |
| Weighted Average Diluted Shares | 14↑2338.3% | 0.56↑61.4% | 0.34↑152.7% | 0.14↑0.0% | 0.14 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.